STATEMENT OF NEED
CLL has an extremely variable course, with some patients having an indolent disease that does not require treatment for many years and others presenting with an aggressive and symptomatic disease that requires immediate intervention. Interpretation of international guidelines on diagnostic and prognostic testing can vary considerably, specifically regarding when to initiate therapy, how to apply prognostic markers during treatment selection, and the optimal regimens and sequences of agents for individual patients. Furthermore, the rapid pace of clinical research has made it difficult for hematology/oncology providers to stay abreast of the latest and most clinically relevant treatment advances.
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with chronic lymphocytic leukemia.
Upon completion of this activity, participants should be able to:
- Evaluate criteria to risk stratify patients with CLL
- Describe mechanisms of treatment resistance in CLL
- Differentiate emerging data on novel therapeutic approaches for patients with previously untreated and relapsed/refractory CLL
Farrukh T. Awan, MD, MS (Chairperson)
Associate Professor of Internal Medicine
The Ohio State University Comprehensive Cancer Center
Nicole Lamanna, MD
Associate Clinical Professor of Medicine
Columbia University Medical Center
Fredrick B. Hagemeister, MD
Professor of Medicine
University of Texas MD Anderson Cancer Center
Stephen E.F. Spurgeon, MD
Associate Professor of Medicine
Oregon Health and Science University
There is no fee to participate in or claim CME credit for this activity.
Please note that the University of Cincinnati and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
Jointly Provided by
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Cincinnati and i3 Health. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
A conflict of interest is created when individuals in a position to control the content of CE have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits. The University of Cincinnati will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. The University of Cincinnati does not endorse any products or services.
Farrukh T. Awan, MD, MS has served on the advisory board for Gilead and Pharmacyclics, and has received grants/research support from Pharmacyclics.
Nicole Lamanna, MD has served on the scientific committee for AbbVie, Celgene, Genentech, Gilead, Pharmacyclics/Janssen, and Verastem. She has received grants/research support from AbbVie, Genentech, Gilead, Pharmacyclics/Janssen, and Verastem. She has served on the advisory board for Celgene.
Fredrick B. Hagemeister, MD has served on the advisory board for Bristol-Myers Squibb, Genentech, Gilead, and Merck.
University of Cincinnati staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.
Disclosures are on file at the University of Cincinnati, Office of Continuing Medical Education.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
UNAPPROVED USE DISCLOSURE
The University of Cincinnati and i3 Health require CME/CE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity was made possible by AbbVie and Pharmacyclics LLC and Janssen Biotech, Inc.